BioCentury | Jan 20, 2021
Product Development

Gritstone sending a mixed-modality COVID vaccine to Phase I

NIAID and the Gates Foundation are betting Gritstone’s antigen delivery and T cell epitope prediction technologies can yield a COVID-19 vaccine with both potent CD8+ T cell immunity and neutralizing antibody...
BioCentury | Jan 12, 2021
Deals

Sanofi joins the myeloid checkpoint movement with Biond deal

Sanofi is staking claims in next-generation checkpoints through a new deal with Israeli biotech Biond around myeloid checkpoint target ILT2.  The deal with Biond Biologics Ltd., which gives the biotech $125 million up front and...
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

Bispecific antibodies are starting to diverge from CAR Ts as they venture into new targets and indications in the clinic.  First-generation T cell-engaging bispecific antibodies have mirrored the...
BioCentury | Dec 1, 2020
Product Development

Moderna moves & Immunocore breaks through: a BioCentury podcast

After its latest readout positioned the company to seek FDA authorization of its COVID-19 vaccine, Moderna has begun to look ahead to unblinding the Phase III trial of mRNA-1273 so participants who received a placebo can be...
BioCentury | Nov 23, 2020
Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

With a positive Phase III readout in metastatic uveal melanoma, Immunocore has become the first company to solve one of the biggest challenges in immuno-oncology: applying T cell-engaging bispecifics to solid tumors.  The data suggest...
BioCentury | Oct 22, 2020
Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies

CRISPR Therapeutics’ first allogeneic CAR T therapy readout supports the idea that the therapeutic class can yield efficacy on par with autologous CAR Ts, without causing graft-versus-host disease. But a patient death raises the possibility allogeneic...
BioCentury | Oct 9, 2020
Emerging Company Profile

A2: targeting lost genetic material to distinguish tumors from normal cells

...month in Molecular Immunology, described a xenograft mouse model of cancer in which absence of the HLA-A*02...
...antigen. The work demonstrated selective killing of the CD19-positive, HLA-A*02-negative tumor cells while sparing CD19-positive, HLA-A*02-positive...
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

The myeloid cell targets that have been generating preclinical attention are moving into the clinical arena, and the first look at data from Merck’s ILT4 program provides an early signal that the strategy...
BioCentury | Aug 6, 2020
Emerging Company Profile

Off-the-shelf cell therapy pioneers, Versant launch Matterhorn to tackle broad range of cancers

Versant’s Ridgeline incubator in Basel has launched Matterhorn with an off-the-shelf MR1T cell therapy designed to address a broader range of cancers than CAR T and TCR therapies. The company raised a $30 million series...
BioCentury | Aug 1, 2020
Translation in Brief

TScan identifies CD8+ T cell COVID-19 epitopes, plus T3 gears up for Phase I of bacterial cancer therapy, a wearable device to monitor PK and a COVID-19 vaccine

SARS-CoV-2 binding sites for cytotoxic T cells TScan Therapeutics Inc. reported in medRxiv that memory CD8 + T cell responses against SARS-CoV-2 are dominated by a few epitopes in SARS-CoV-2. An analysis of samples from...
Items per page:
1 - 10 of 683